JP3836066B2 - Cosmetics - Google Patents
Cosmetics Download PDFInfo
- Publication number
- JP3836066B2 JP3836066B2 JP2002304097A JP2002304097A JP3836066B2 JP 3836066 B2 JP3836066 B2 JP 3836066B2 JP 2002304097 A JP2002304097 A JP 2002304097A JP 2002304097 A JP2002304097 A JP 2002304097A JP 3836066 B2 JP3836066 B2 JP 3836066B2
- Authority
- JP
- Japan
- Prior art keywords
- phosphatidylcholine
- acid
- fatty acid
- poe
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002537 cosmetic Substances 0.000 title claims description 36
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 150000004665 fatty acids Chemical group 0.000 claims description 14
- 150000004671 saturated fatty acids Chemical group 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 19
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000003904 phospholipids Chemical class 0.000 description 14
- -1 fatty acid monocarboxylic acids Chemical class 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 11
- 239000011668 ascorbic acid Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 210000002969 egg yolk Anatomy 0.000 description 7
- 238000005886 esterification reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003531 protein hydrolysate Substances 0.000 description 6
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229940072107 ascorbate Drugs 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000012024 dehydrating agents Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000010775 animal oil Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 125000005639 glycero group Chemical group 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 101100379142 Mus musculus Anxa1 gene Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004260 Potassium ascorbate Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 2
- ASWBNKHCZGQVJV-QHCPKHFHSA-N [(2s)-3-hexadecanoyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-QHCPKHFHSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229940074358 magnesium ascorbate Drugs 0.000 description 2
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000019275 potassium ascorbate Nutrition 0.000 description 2
- 229940017794 potassium ascorbate Drugs 0.000 description 2
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- NTSDDIPBDQOVPE-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC(C)C)(=O)OCCCCCCCCCCCCCCCCCC.C(CCCCCCCCCCCCCCC(C)C)(=O)OCCCCCCCCCCCCCCCCCC Chemical compound C(CCCCCCCCCCCCCCC(C)C)(=O)OCCCCCCCCCCCCCCCCCC.C(CCCCCCCCCCCCCCC(C)C)(=O)OCCCCCCCCCCCCCCCCCC NTSDDIPBDQOVPE-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- RCYWWJBNPIWJMJ-UHFFFAOYSA-N [4-(hexadecanoyloxymethyl)-5-hydroxy-6-methylpyridin-3-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCCCCCCCCCC RCYWWJBNPIWJMJ-UHFFFAOYSA-N 0.000 description 1
- PAUSGZCRNOTKPK-UHFFFAOYSA-N [5-hydroxy-6-methyl-4-(octanoyloxymethyl)pyridin-3-yl]methyl octanoate Chemical compound CCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCC PAUSGZCRNOTKPK-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003284 horn Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940095042 pyridoxine dipalmitate Drugs 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000005472 straight-chain saturated fatty acid group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940099373 sudan iii Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、特定の脂肪酸残基を有するホスファチジルコリンと硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを含有した肌改善効果に優れた新規な化粧料に関する。
【0002】
【従来の技術】
肌荒れを改善するため、あるいは健常な皮膚を維持するためには、角質層の水分含有量の低下を防止し、正常な皮膚機能を維持することが必要である。従来、その目的で化粧料に使用されている多価アルコールや糖類等の保湿剤は皮膚への水分補給のみに依存し、一方、動植物油脂やエステル油等の柔軟剤は皮膚からの水分蒸散防止のみに依存している。したがって、その効果はいずれも一過性であり、角質層の水分保持機能を亢進させて本質的に肌荒れを改善するというものでなかった。
【0003】
このような状況下、肌荒れ等の肌を改善するために、あるいは保湿効果を改善するためにリン脂質と硬タンパク質を含有した化粧料が提案されている。例えば、特開平5−70333号公報(特許文献1)には、硬タンパク質の1種であるコラーゲンやエラスチン等のタンパク質及び/又はその加水分解物とリン脂質との複合体を含有した化粧料が、特開昭61−251605号公報(特許文献2)には、保湿効果可溶性コラーゲンとレシチンを含有した化粧料が提案されている。
【0004】
しかしながら、上記提案のリン脂質あるいは従来使用されているリン脂質は、リン脂質のグリセロ骨格の1位及び2位の脂肪酸残基が長鎖脂肪酸である大豆レシチン、卵黄レシチン等の動植物由来のリン脂質、あるいはこれらのリン脂質より例えば、ホスファチジルコリ等のリン脂質成分を分画したものや水素添加処理を施した水添レシチン等であり、従来のリン脂質及び硬タンパク質を含有していない従前の保湿剤や柔軟剤を含有させた化粧料に比べ、肌荒れを改善する効果は、確かに優れているものの、未だ満足できる程の十分な効果を有するとは言い難く、更なる改善が要望されている。
【0005】
また、特開昭59−1404号公報(特許文献3)には、コラーゲン等のタンパク質とリン脂質とを含有した乳化化粧料が提案されている。特開昭59−1404号公報(特許文献3)記載の乳化化粧料は、安全性の高い天然由来の物質を用いて安定なエマルジョンを得ることを目的としているが、肌荒れ改善効果については、上述した特許文献の化粧料と同様、未だ満足できる程の十分な効果を有するとは言い難いものであった。
【0006】
【特許文献1】
特開平5−70333号公報
【特許文献2】
特開昭61−251605号公報
【特許文献3】
特開昭59−1404号公報
【0007】
【発明が解決しようとする課題】
そこで本発明の目的は、肌改善効果に優れた化粧料を提供することである。
【0008】
【課題を解決するための手段】
本発明者は、上記の目的を達成すべくレシチンの主成分であるホスファチジルコリンの脂肪酸残基について鋭意研究を重ねた結果、グリセロ骨格の1位の脂肪酸残基が直鎖型の長鎖脂肪酸であり、2位が直鎖飽和型の中鎖脂肪酸であるホスファチジルコリンを、硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上と組合わせて用いるならば、意外にも肌改善効果に優れた化粧料が得られることを見出し本発明を完成するに至った。
すなわち、本発明は、
(1) 一般式
[化1]
(式中、R1はC14〜C22の直鎖脂肪酸残基であり、R2はC8〜C10の直鎖飽和脂肪酸残基である)
で表されるホスファチジルコリンと、硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを含有した化粧料、
(2) 化粧料全体に対し0.001〜5%の前記ホスファチジルコリンと、0.005〜10%の硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを含有した(1)の化粧料、
を提供することである。
【0009】
【発明の実施の形態】
以下本発明を説明する。なお、本発明において特に限定していない場合は、「%」は「質量%」、また「部」は「質量部」を意味する。
本発明で使用するホスファチジルコリンは、R1が上記したとおりC14〜C22の直鎖脂肪酸残基であるが、この炭素の個数は、一般に天然のホスファチジルコリンやリゾホスファチジルコリンにおいて、該グリセロール骨格の1位の水酸基とエステル結合している脂肪酸残基の直鎖炭化水素部分(C−C結合が飽和あるいは不飽和)とほぼ同じである。よって、天然由来のホスファチジルコリンやリゾホスファチジルコリンを原料として本発明に使用するホスファチジルコリンを製造したときには、一般にR1はC14〜C22の範囲に入る多種類の直鎖脂肪酸残基を含むものである。また、例えば、1−パルミトイルリゾホスファチジルコリン等を原料として本発明に使用するホスファチジルコリンを製造したときは、R1はC14〜C22の範囲に入る(例えばC16)1種類の直鎖飽和脂肪酸残基のみを含むものである。
【0010】
また、本発明におけるR2は、上記した通りC8〜C10の直鎖飽和脂肪酸残基である。R2相当部分の炭素数がC14〜C22の範囲にある天然由来のホスファチジルコリンと比べると、炭素数が一段と低い値になっている点で天然由来のホスファチジルコリンと大きく異なる。
【0011】
本発明に使用するホスファチジルコリンの製造方法の一例を、以下に天然のリゾホスファチジルコリンを出発原料とする製造例でもって説明する。なお、本発明はこの製造方法に限定されるものではない。
【0012】
(1)エステル化反応
天然のリゾホスファチジルコリン(1位がエステル結合しており、R1に相当する脂肪酸残基がほぼC14〜C22の直鎖型のもの:例えば、卵黄リゾホスファチジルコリン、大豆リゾホスファチジルコリン等)の2位の水酸基を下記の方法に準じてC8〜C10の飽和n−アルキル酸でエステル化する。
リゾホスファチジルコリン(1モル)、n−アルキル酸(1.5〜2.0モル)、エステル化触媒として4−ジメチルアミノピリジン(2.2〜2.6モル)および溶媒としてクロロホルム(リゾホスファチジルコリン質量の約60倍量)を、窒素気流下氷冷しながら混合する(混合液はほぼ10℃)。この混合液に、エステル化を促進させるために、脱水剤N,N'−ジシクロヘキシルカルボジイミド(2.5〜3.0モル)をその約6倍量のクロロホルム溶液として滴下する。次いで室温において遮光下、窒素気流下で撹拌しながら40時間保持し、エステル化反応を行う。
なお、エステル化反応で用いるn−アルキル酸を具体的に示すと、炭素数が8個のn−オクタン酸、炭素数が9個のn−ノナン酸、炭素数が10個のn−デカン酸である。
【0013】
(2)脱水剤等の除去処理
エステル化反応終了後の反応液から減圧下溶媒(クロロホルム)を留去する。その残留物にクロロホルム溶液[クロロホルム:メタノール:水=5:4:1(容量比)]を、原料のリゾホスファチジルコリン1gに対して約75mlの割合で添加し、撹拌後、主としてN,N'−ジシクロヘキシルカルボジイミドの分解物からなる不溶物をガラスフィルター(目径:20〜30μ)で濾過除去する。なお、クロロホルム溶液を加えるのは、未反応(未分解)脱水剤を分解させ、有機溶媒に不溶なものにするためである。
【0014】
次いで、このようにして脱水剤(分解物)を除去して得られた濾液は、これとほぼ同容量のイオン交換樹脂[アンバーライトIRA−45とアンバーライトIRC−50との1:1(容量比)混合物]を充填したカラムに通過させ、未反応の(過剰の)n−アルキル酸およびエステル化触媒4−ジメチルアミノピリジンを樹脂に吸着除去させる。得られた溶出液は、樹脂のクロロホルム溶液(脱水剤除去の際に用いた溶液と同じものでよく、しかも同量である)による第一洗浄液と合わせた後、減圧下で溶媒(クロロホルム、メタノール、水)を留去する。残留物を上記クロロホルム溶液の1/3容量のクロロホルムに溶解させ、生じる不溶物(主として残存しているN,N'−ジシクロヘキシルカルボジイミドの分解物)を更にガラスフィルターで濾別除去する。
【0015】
(3)目的のホスファチジルコリンの分画
上記の除去処理によって得られた濾液には目的とするホスファチジルコリンの他、上記の処理によっても除去しえない幾分かのn−アルキル酸や4−ジメチルアミノピリジンが依然残留しているので、これらを除くために該濾液を次いで以下に示すシリカゲルカラムクロマト処理に付す。
すなわち、濾液をその8倍容量のシリカゲルを充填したカラムに供した後、下記の3種類の混合溶液を用いて段階的に溶出操作を行なう。
【0016】
▲1▼第一溶出操作
クロロホルム:メタノール=9:1(容量比)の混合溶媒を原料のリゾホスファチジルコリン1gに対して約500mlの割合で用いる。この溶出操作により主としてn−アルキル酸が溶出される。
なお、この操作の終了は、100ml画分で集めた溶出液をそれぞれ溶媒留去した上で残渣(n−アルキル酸)が認められなくなったことを確認した時点とする。
【0017】
▲2▼第二溶出操作
クロロホルム:メタノール=1:1(容量比)の混合溶媒を原料のリゾホスファチジルコリン1gに対して約500mlの割合で用いる。この溶出操作により主として4−ジメチルアミノピリジンが溶出される。
なお、この操作の終了は、溶出液の一部をTLC(薄層クロマトグラフィー)で展開後、検出を254nmの紫外線ランプ照射により行ない、黒色スポット(紫外線吸収物質4−ジメチルアミノピリジンの存在は蛍光部を黒色化する)が認められなくなったことを確認した時点とする。
【0018】
▲3▼第三溶出操作
クロロホルム:メタノール=3:7(容量比)の混合溶媒を原料のリゾホスファチジルコリン1gに対して約500mlの割合で用いる。この溶出操作により目的とするホスファチジルコリンが溶出される。
なお、この操作の終了は、溶出液の一部をTLCで展開後、検出をDittmer試薬噴霧により行ない、リン脂質の存在を示す青色スポットが認められなくなったことを確認した時点とする。
【0019】
上記の第三溶出操作で得られる溶出液は、次いで減圧下で溶媒を留去し、目的とするホスファチジルコリンを得る。収率は、60〜70%程度である。
以上の製造方法は、天然のリゾホスファチジルコリンを出発原料とする方法であるが、他の原料、例えば、1−パルミトイルリゾホスファチジルコリン等を出発原料とする場合も上記に準じて行なえばよい。
【0020】
本発明に使用する硬タンパク質とは、動物の皮膚、骨、腱、靭帯、肺、毛、爪及び角等や絹等の繊維に含まれる高分子タンパク質、例えば、コラーゲン、エラスチン、ケラチン、フィブロイン等であり、これらの誘導体とは、例えば、脂肪酸モノカルボン酸から誘導されるアシル化物、ジカルボン酸から誘導されるサクシニル化物、ディスアミド化物等である。また、硬タンパク質の加水分解物とは、酸、アルカリ、酵素等、公知の方法により上記硬タンパク質を加水分解して得られたものをいい、本発明では、加水分解後の分子量により限定されるものではない。
【0021】
本発明の化粧料は、上述したホスファチジルコリンと硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを含有したものであるが、ホスファチジルコリンの含有量は、化粧料全体に対し0.001〜5%が好ましく、0.005〜3%がより好ましい。また、硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上の含有量は、その合計量が化粧料全体に対し0.005〜10%が好ましく、0.01〜8%がより好ましい。いずれの場合も、その含有量が少なすぎると十分な肌改善効果が得られ難く、一方、多すぎたとしても、それ以上の肌改善効果が得られ難く経済的でないことから好ましくない。なお、上記含有量において、化粧料の剤形が粉末状の場合は、該粉末状の化粧料を使用する際に水戻ししたときの含有量を意味する。
【0022】
本発明の化粧料は、上述したホスファチジルコリンと硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを一原料として用いる他は、常法に則り製造すれば良く、化粧品の剤形としては、化粧水、乳液、クリーム、ジェル、粉末状等が挙げられる。また、本発明の化粧料には、化粧料に一般的に用いられる多価アルコール、油性成分、低級アルコール、保湿剤、美白剤、増粘剤、防腐剤、界面活性剤等、その他の成分を本発明の効果を損なわない範囲内で適宜配合することができる。
【0023】
その他の成分の一例を挙げれば、次のとおりである。
多価アルコールとしては、例えば、エチレングリコール、ポリエチレングリコール、プロピレングリコール、1,3-ブチレングリコール、1,4-ブチレングリコール、ジプロピレングリコール、グリセリン、ジグリセリン、ポリグリセリン、ペンチレングリコール、イソプレングリコール、グルコース、マルトース、ショ糖、フルクトース、キシリトール、ソルビトール、マルトトリオース、エリスリトール等が挙げられる。
【0024】
油性成分としては、例えば、油溶性ビタミン類(ビタミンA、ビタミンD、ビタミンE、ビタミンF、ビタミンK群のビタミン、ジカプリル酸ピリドキシン、ジパルミチン酸ピリドキシン、ジパルミチン酸アスコルビル、モノパルミチン酸アスコルビル、モノステアリン酸アスコルビル等のビタミン誘導体等)、油溶性ホルモン類(エストラジオール、エチニルエストラジオール、エストロン、ジエチルスチルペストロール等)、油溶性色素類(スダンIII、フルオレセン等)、油溶性紫外線吸収剤類(オキシベンゾン、2,5-ジイソプロピル桂皮酸メチル等)、動植物油類(アボガド油、オリーブ油等の動植物油、ジグリセリン脂肪酸エステル等の誘導体等)、高級脂肪族炭化水素類(スクワラン、スクワレン、流動パラフィン等)、高級脂肪酸類(ステアリン酸、イソステアリン酸、オレイン酸等)、高級アルコール(ステアリルアルコール、イソステアリルアルコール、オクチルドデカノール等)、エステル油類(イソプロピルミリステート、オクチルドデシルミリステート等)、コレステロール等のステロール類、スフィンゴ脂質(セラミド、セレブロシド、スフィンゴミエリン等及びこれらの誘導体等)等が挙げられる。
【0025】
低級アルコールとしては、例えば、エチルアルコール、プロピルアルコール、イソプロピルアルコール、ブチルアルコール、イソブチルアルコール等が挙げられる。
【0026】
保湿剤としては、例えば、ヒアルロン酸、デルマタン硫酸、コンドロイチン硫酸、ヘパラン硫酸、ケラタン硫酸、ヘパリン、キチン等のムコ多糖類又はこれらの塩、ピロリドンカルボン酸又はその塩、トレハロース等が挙げられる。
【0027】
美白剤としては、例えば、アスコルビン酸類(アスコルビン酸、アスコルビン酸ナトリウム、アスコルビン酸カリウム、アスコルビン酸マグネシウム、アスコルビン酸カルシウム等のアスコルビン酸塩、アスコルビン酸−2−硫酸ナトリウム等のアスコルビン酸硫酸エステル、アスコルビルリン酸、アスコルビン酸リン酸ナトリウム、アスコルビン酸リン酸カリウム、アスコルビン酸リン酸マグネシウム、アスコルビン酸リン酸カルシウム等のアスコルビン酸リン酸エステル、アスコルビン酸モノステアレート、アスコルビン酸モノパルミテート、アスコルビン酸モノオレエート、アスコルビン酸ジステアレート、アスコルビン酸ジパルミテート、アスコルビン酸ジオレエート等のアスコルビン酸脂肪酸エステル、アスコルビン酸−2−グルコシド等のアスコルビン酸グルコシド等)アルブチン、プラセンタエキス、コウジ酸、米糠抽出物、ルシノール、クジンエキス等が挙げられる。
【0028】
増粘剤としては、例えば、カルボキシメチルセルロース、カルボキシビニルポリマー、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、メチルセルロース、エチルセルロース、キサンタンガム、カラギーナン、アルギン酸塩、ペクチン、アラビアガム、カラヤガム、トラガントガム、タマリンドガム、カンテン末、ポリエチレングリコール等が挙げられる。
【0029】
防腐剤としては、例えば、メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン等のパラベン類、フェノキシエタノール等が挙げられる。
【0030】
界面活性剤としては、例えば、ポリオキシエチレン[以下、POE-と略す]アルキルエーテル(POE-オレイルエーテル、POE-セチルエーテル等)、POE-分岐アルキルエーテル(POE-オクチルドデシルアルコール、POE-2-デシルテトラデシルアルコール等)、ソルビタンエステル(ソルビタンモノオレエート、ソルビタンイモノイソステアレート、ソルビタンモノラウレート等)、POE-ソルビタンエステル(POE-ソルビタンモノオレエート、POE-ソルビタンモノイソステアレート、POE-ソルビタンモノラウレート等)、グリセリン脂肪酸エステル(グリセリルモノオレエート、グリセリルモノステアレート、グリセリルモノミリステート等)、POE-グリセリン脂肪酸エステル(POE-グリセリルモノオレエート、POE-グリセリルモノステアレート、POE-グリセリルモノミリステート等)、POE-ジヒドロコレステロールエーテル、POE-硬化ヒマシ油脂肪酸エステル(POE-硬化ヒマシ油、POE-硬化ヒマシ油イソステアレート等)、POE-アルキルアリールエーテル(POE-オクチルフェノールエーテル等)、グリセロールエーテル(グリセロールモノイソステアレート、グリセロールモノミリステート等)、POE-グリセロールエーテル(POE-グリセロールモノイソステアレート、POE-グリセロールモノミリステート等)、ポリグリセリン脂肪酸エステル(ジグリセリルモノステアレート、デカグリセリルイソステアレート、デカグリセリルデカイソステアレートジステアリルジイソステアレート等)、高級脂肪酸(ミリスチン酸、ステアリン酸、パルミチン酸、ベヘン酸、イソステアリン酸、オレイン酸等)の塩(カリウム、ナトリウム、ジエタノールアミン、トリエタノールアミン等)、リン脂質(ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジン酸、ホスファチジルイノシトール、ホスファチジルセリン及びこれらのリゾ体)等が挙げられる。
【0031】
【実施例】
次に、本発明を実施例及び試験例に基づき、さらに詳細に説明する。なお、本発明はこれらに限定されるものではない。
【0032】
[実施例1]及び[比較例1〜4]
表1に示す配合割合で、油相と水相の各原料を70℃にて均一に混合し、油相を撹拌させながら水相を徐々に添加して乳化した後、引続き低速で撹拌させながら約30℃まで冷却してクリームを調製した。
【0033】
なお、表中のMCPCは本発明で使用するホスファチジルコリンであり、その調製は、R1がC14〜C22の直鎖脂肪酸残基を含有する卵黄リゾホスファチジルコリン(キユーピー(株)製「卵黄リゾレシチンLPC-1(商品名)」)と炭素数が8個のn−オクタン酸を原料に上述した製造方法の(1)〜(3)に準じて行なった。各原料の量は、次の通りである。
(a)卵黄リゾホスファチジルコリン 20g
その他の原料は、卵黄リゾホスファチジルコリン1モルに対し、
(b)n−オクタン酸 1.8モル
(c)4−ジメチルアミノピリジン 2.4モル
(d)N,N'−ジシクロヘキシルカルボジイミド 2.8モル
の比となる量の、(b)、(c)及び(d)を用いた。
【0034】
また、表中のリゾホスファチジルコリン及び水素添加リン脂質は、それぞれMCPCの原料として使用したキユーピー(株)製の「卵黄リゾレシチンLPC-1(商品名)」及びキユーピー(株)の「卵黄レシチンPL-100P(商品名)」を使用した。
【0035】
【表1】
【0036】
【試験例】
[試験例1]
実施例1及び比較例1〜4で得られた各クリームを、慢性的に肌が乾燥し肌荒れに悩んでいる75名の女性(平均年齢30歳)を被験者としてパネルテストを実施した。
【0037】
まず、肌の状態を確認するため、予め事前アンケートを実施し、この事前アンケート結果を基に、肌の状態が偏らないように1群15名の5群に分けた。1つの群に対し、上記何れか1つのクリームを朝及び就寝前に6週間にわたって使用させ、使用前後の肌の状態についてアンケート調査を行なった。アンケート調査の内容は、肌の状態を以下の評価基準に照らして回答させたものである。得られた結果を表2に示す。
なお、被験者にはどのクリームを使用させたか明らかにしなかった。
【0038】
<ランク>
A:非常に改善された。
B:改善された。
C:やや改善された。
D:変化が認められない。
<総合評価>
◎:「A:非常に改善された。」と回答した被験者が8名以上
○:「A:非常に改善された。」と回答した被験者が8名未満、かつ「A:非常に改善された。」あるいは「B:改善された。」と回答した被験者が8名以上
△:「A:非常に改善された。」あるいは「B:改善された。」と回答した被験者が3名以上8名未満
×:「A:非常に改善された。」あるいは「B:改善された。」と回答したパネラーが3名未満
【0039】
【表2】
【0040】
表2より、本発明のMCPCと硬タンパク質加水分解物(加水分解コラーゲン)を含有した化粧料(実施例1)は、優れた肌改善効果を有することが理解される。つまり、硬タンパク質加水分解物のみを含有した化粧料(比較例1)及びMCPCのみを含有した化粧料(比較例4)は、殆どの被験者が「やや改善された」と回答しており、肌改善効果が期待できるものではなかった。また、硬タンパク質加水分解物とリゾホスファチジルコリン又は水素添加リン脂質とを含有した化粧料(比較例2又は3)は、前記硬タンパク質加水分解物のみ、あるいはMCPCのみ含有した化粧料に比べ、若干、改善されているものの、過半数の被験者が「やや改善された」と回答しており、十分に肌改善効果を有するとは言い難いものであった。
これに対しMCPCと硬タンパク質加水分解物とを含有した化粧料(実施例1)は、殆どの被験者が「非常に改善された」あるいは「改善された」と回答しており、他の化粧料に比べ優れた肌改善効果を有していた。
【0041】
[実施例2]
下記に示す配合割合で、油相と水相の各原料を室温で、あるいは必要に応じ一時加温して均一に分散した後、油相を撹拌させながら水相を徐々に添加・混合し化粧水を調製した。
得られた化粧水は、肌改善効果に優れたものであった。
なお、MCPCは、実施例1においてMCPCを製造する際に原料として用いたn−オクタン酸をn−デカン酸に換えて、それ以外は実施例1に準じて製造したものである。
【0042】
【0043】
【発明の効果】
以上述べたとおり、本発明の化粧料は、グリセロ骨格の1位の脂肪酸残基が直鎖型の長鎖脂肪酸、2位が直鎖飽和型の中鎖脂肪酸であるホスファチジルコリンと硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを組合わせることにより、従来使用されていた大豆レシチン、卵黄レシチン又はこれらの水素添加処理品、あるいはモノアシル型のリゾレシチンと硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを組合わせた化粧料に比べ、優れた肌改善効果を有する化粧料が得られる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a novel cosmetic excellent in skin improvement effect comprising phosphatidylcholine having a specific fatty acid residue and at least one selected from hard proteins and hydrolysates or derivatives thereof.
[0002]
[Prior art]
In order to improve rough skin or maintain healthy skin, it is necessary to prevent a decrease in the moisture content of the stratum corneum and maintain normal skin function. Conventionally, moisturizers such as polyhydric alcohols and sugars used in cosmetics for that purpose depend only on hydration of the skin, while softeners such as animal and vegetable oils and ester oils prevent moisture transpiration from the skin. Rely only on. Therefore, all of the effects were transient, and the water retention function of the stratum corneum was enhanced, and the rough skin was not essentially improved.
[0003]
Under such circumstances, cosmetics containing phospholipids and hard proteins have been proposed in order to improve skin such as rough skin or to improve the moisturizing effect. For example, JP-A-5-70333 (Patent Document 1) discloses a cosmetic containing a complex of a protein such as collagen or elastin and / or a hydrolyzate thereof and a phospholipid, which is a kind of hard protein. JP-A 61-251605 (Patent Document 2) proposes a cosmetic containing moisturizing effect soluble collagen and lecithin.
[0004]
However, the above proposed phospholipids or conventionally used phospholipids are phospholipids derived from animals and plants such as soybean lecithin and egg yolk lecithin in which the fatty acid residues at positions 1 and 2 of the glycero skeleton of the phospholipid are long chain fatty acids. Or, for example, a fraction obtained by fractionating a phospholipid component such as phosphatidyl coli or hydrogenated lecithin from these phospholipids, and a conventional moisturizing agent that does not contain conventional phospholipids and hard proteins. Compared to cosmetics containing softeners and softeners, the effect of improving rough skin is certainly excellent, but it is still difficult to say that it has a satisfactory enough effect, and further improvements are required. .
[0005]
JP-A-59-1404 (Patent Document 3) proposes an emulsified cosmetic containing a protein such as collagen and a phospholipid. The emulsified cosmetic described in JP-A-59-1404 (Patent Document 3) is intended to obtain a stable emulsion by using a highly safe naturally-derived substance. As with the cosmetics disclosed in the patent literature, it was difficult to say that the cosmetics still have a satisfactory effect.
[0006]
[Patent Document 1]
JP-A-5-70333 [Patent Document 2]
Japanese Patent Laid-Open No. 61-251605 [Patent Document 3]
Japanese Patent Application Laid-Open No. 59-1404
[Problems to be solved by the invention]
Then, the objective of this invention is providing the cosmetics excellent in the skin improvement effect.
[0008]
[Means for Solving the Problems]
As a result of intensive research on the fatty acid residue of phosphatidylcholine, which is the main component of lecithin, to achieve the above object, the present inventor found that the fatty acid residue at position 1 of the glycero skeleton is a linear long-chain fatty acid. If phosphatidylcholine, which is a straight-chain saturated medium chain fatty acid at the 2-position, is used in combination with at least one selected from hard proteins and hydrolysates or derivatives thereof, it is surprisingly excellent in skin improvement effect The present inventors have found that a cosmetic material can be obtained, and have completed the present invention.
That is, the present invention
(1) General formula [Formula 1]
(Wherein R 1 is a C 14 -C 22 linear fatty acid residue and R 2 is a C 8 -C 10 linear saturated fatty acid residue)
A cosmetic comprising phosphatidylcholine represented by: at least one selected from hard proteins and hydrolysates or derivatives thereof;
(2) Containing 0.001 to 5% of the phosphatidylcholine, and 0.005 to 10% of a hard protein and a hydrolyzate or derivative thereof, based on the entire cosmetic (1) Cosmetics,
Is to provide.
[0009]
DETAILED DESCRIPTION OF THE INVENTION
The present invention will be described below. In the present invention, unless otherwise specified, “%” means “mass%” and “parts” means “parts by mass”.
The phosphatidylcholine used in the present invention is a C 14 to C 22 linear fatty acid residue as described above for R 1 , and this carbon number is generally the first position of the glycerol skeleton in natural phosphatidylcholine and lysophosphatidylcholine. It is almost the same as the straight-chain hydrocarbon part (CC bond is saturated or unsaturated) of the fatty acid residue which is ester-bonded to the hydroxyl group. Therefore, when phosphatidylcholine used in the present invention is produced using naturally-derived phosphatidylcholine or lysophosphatidylcholine as a raw material, R 1 generally contains many types of linear fatty acid residues that fall within the range of C 14 to C 22 . In addition, for example, when 1-palmitoyl lysophosphatidylcholine or the like is used as a raw material and phosphatidylcholine used in the present invention is produced, R 1 falls within the range of C 14 to C 22 (for example, C 16 ). It contains only groups.
[0010]
Also, R 2 in the present invention is a straight-chain saturated fatty acid residues as C 8 -C 10 described above. Compared with naturally occurring phosphatidylcholine in which the carbon number of the R 2 equivalent portion is in the range of C 14 to C 22 , the carbon number is significantly different from that of naturally occurring phosphatidylcholine.
[0011]
An example of a method for producing phosphatidylcholine used in the present invention will be described below with production examples using natural lysophosphatidylcholine as a starting material. The present invention is not limited to this manufacturing method.
[0012]
(1) Esterification reaction Natural lysophosphatidylcholine (1st-position ester-linked, fatty acid residue corresponding to R 1 is a straight chain type having approximately C 14 to C 22 : for example, egg yolk lysophosphatidylcholine, soybean lyso The hydroxyl group at the 2-position of phosphatidylcholine or the like is esterified with a C 8 -C 10 saturated n-alkyl acid according to the following method.
Lysophosphatidylcholine (1 mol), n-alkyl acid (1.5-2.0 mol), 4-dimethylaminopyridine (2.2-2.6 mol) as esterification catalyst and chloroform (lysophosphatidylcholine mass) as solvent About 60 times the amount) is mixed under ice-cooling under a nitrogen stream (the mixture is approximately 10 ° C.). In order to promote esterification, a dehydrating agent N, N′-dicyclohexylcarbodiimide (2.5 to 3.0 mol) is dropped into this mixed solution as a chloroform solution of about 6 times its amount. Next, the esterification reaction is carried out at room temperature for 40 hours with stirring in a nitrogen stream under light shielding.
Specific examples of the n-alkyl acid used in the esterification reaction include n-octanoic acid having 8 carbon atoms, n-nonanoic acid having 9 carbon atoms, and n-decanoic acid having 10 carbon atoms. It is.
[0013]
(2) Removal of dehydrating agent, etc. The solvent (chloroform) is distilled off from the reaction solution after completion of the esterification reaction under reduced pressure. A chloroform solution [chloroform: methanol: water = 5: 4: 1 (volume ratio)] was added to the residue at a ratio of about 75 ml with respect to 1 g of raw material lysophosphatidylcholine, and after stirring, mainly N, N′- The insoluble matter consisting of the decomposition product of dicyclohexylcarbodiimide is removed by filtration with a glass filter (diameter: 20 to 30 μm). The reason why the chloroform solution is added is to decompose the unreacted (undecomposed) dehydrating agent to make it insoluble in the organic solvent.
[0014]
Subsequently, the filtrate obtained by removing the dehydrating agent (decomposed product) in this way was almost the same capacity as the ion exchange resin [1: 1 (capacity of Amberlite IRA-45 and Amberlite IRC-50]. Ratio) mixture] and unreacted (excess) n-alkyl acid and esterification catalyst 4-dimethylaminopyridine are adsorbed and removed by the resin. The obtained eluate was combined with the first washing solution with a chloroform solution of resin (the same solution as that used for removing the dehydrating agent and the same amount), and then the solvent (chloroform, methanol) under reduced pressure. Water). The residue is dissolved in 1/3 volume of chloroform of the above chloroform solution, and the resulting insoluble matter (mainly, the remaining decomposition product of N, N′-dicyclohexylcarbodiimide) is further removed by filtration with a glass filter.
[0015]
(3) Fractionation of target phosphatidylcholine In addition to the target phosphatidylcholine, the filtrate obtained by the above removal treatment contains some n-alkyl acids and 4-dimethylaminopyridine that cannot be removed by the above treatment. Still remain, the filtrate is then subjected to silica gel column chromatography as described below to remove them.
That is, after subjecting the filtrate to a column packed with 8 times the volume of silica gel, elution is performed stepwise using the following three types of mixed solutions.
[0016]
(1) First elution operation A mixed solvent of chloroform: methanol = 9: 1 (volume ratio) is used at a ratio of about 500 ml to 1 g of raw material lysophosphatidylcholine. By this elution operation, n-alkyl acid is mainly eluted.
The end of this operation is the time when it was confirmed that no residue (n-alkyl acid) was observed after evaporating the eluate collected in 100 ml fractions.
[0017]
(2) Second elution operation A mixed solvent of chloroform: methanol = 1: 1 (volume ratio) is used at a ratio of about 500 ml to 1 g of raw material lysophosphatidylcholine. By this elution operation, 4-dimethylaminopyridine is mainly eluted.
This operation is completed by developing a part of the eluate by TLC (thin layer chromatography) and then detecting it by irradiation with an ultraviolet lamp at 254 nm. A black spot (the presence of the ultraviolet absorbing substance 4-dimethylaminopyridine is fluorescent). The time when it is confirmed that the blackening of the part is no longer recognized.
[0018]
(3) Third elution operation A mixed solvent of chloroform: methanol = 3: 7 (volume ratio) is used at a ratio of about 500 ml with respect to 1 g of raw material lysophosphatidylcholine. The target phosphatidylcholine is eluted by this elution operation.
This operation is completed when a part of the eluate is developed by TLC and then detected by Dittmer reagent spraying to confirm that no blue spots indicating the presence of phospholipids are observed.
[0019]
In the eluate obtained by the third elution operation, the solvent is then distilled off under reduced pressure to obtain the desired phosphatidylcholine. The yield is about 60 to 70%.
The above production method is a method using natural lysophosphatidylcholine as a starting material, but may be performed in the same manner as described above when other starting materials such as 1-palmitoyl lysophosphatidylcholine are used as starting materials.
[0020]
The hard protein used in the present invention is a polymer protein contained in fibers such as animal skin, bones, tendons, ligaments, lungs, hairs, nails and horns and silk, such as collagen, elastin, keratin, fibroin, etc. These derivatives are, for example, acylated products derived from fatty acid monocarboxylic acids, succinylated products and disamidated products derived from dicarboxylic acids. Further, the hard protein hydrolyzate refers to a product obtained by hydrolyzing the hard protein by a known method such as acid, alkali, enzyme, etc. In the present invention, it is limited by the molecular weight after hydrolysis. It is not a thing.
[0021]
The cosmetic of the present invention contains the above-described phosphatidylcholine and at least one selected from a hard protein and a hydrolyzate thereof or a derivative thereof. The content of phosphatidylcholine is 0. 001 to 5% is preferable, and 0.005 to 3% is more preferable. In addition, the content of at least one or more selected from hard proteins and hydrolysates or derivatives thereof is preferably 0.005 to 10%, more preferably 0.01 to 8%, based on the total amount of the cosmetic. preferable. In either case, if the content is too small, it is difficult to obtain a sufficient skin improvement effect. On the other hand, if the content is too large, it is difficult to obtain a further skin improvement effect, which is not preferable. In addition, in the said content, when the dosage form of cosmetics is a powder form, it means content when it rehydrates, when using this powdery cosmetic composition.
[0022]
The cosmetic of the present invention may be produced according to a conventional method, except that the above-described phosphatidylcholine and at least one selected from hard proteins and hydrolysates or derivatives thereof are used as one raw material. Examples thereof include lotions, emulsions, creams, gels, powders and the like. Further, the cosmetic of the present invention contains other components such as polyhydric alcohols, oily components, lower alcohols, moisturizers, whitening agents, thickeners, preservatives, surfactants and the like generally used in cosmetics. It can mix | blend suitably within the range which does not impair the effect of this invention.
[0023]
An example of other components is as follows.
Examples of the polyhydric alcohol include ethylene glycol, polyethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, dipropylene glycol, glycerin, diglycerin, polyglycerin, pentylene glycol, isoprene glycol, Glucose, maltose, sucrose, fructose, xylitol, sorbitol, maltotriose, erythritol and the like can be mentioned.
[0024]
Examples of the oil component include oil-soluble vitamins (vitamin A, vitamin D, vitamin E, vitamin F, vitamin K group vitamins, pyridoxine dicaprylate, pyridoxine dipalmitate, ascorbyl dipalmitate, ascorbyl monopalmitate, mono Vitamin derivatives such as ascorbyl stearate), oil-soluble hormones (estradiol, ethinylestradiol, estrone, diethylstilpestrol, etc.), oil-soluble pigments (sudan III, fluorescene, etc.), oil-soluble UV absorbers (oxybenzone, 2,5-diisopropyl cinnamate methyl), animal and vegetable oils (animal and vegetable oils such as avocado oil and olive oil, derivatives such as diglycerin fatty acid ester), higher aliphatic hydrocarbons (such as squalane, squalene and liquid paraffin), Higher fatty acids (Stearic acid, isostearic acid, oleic acid, etc.), higher alcohols (stearyl alcohol, isostearyl alcohol, octyldodecanol, etc.), ester oils (isopropyl myristate, octyldodecyl myristate, etc.), sterols such as cholesterol, Examples include sphingolipids (ceramide, cerebroside, sphingomyelin, etc., and derivatives thereof).
[0025]
Examples of the lower alcohol include ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, isobutyl alcohol and the like.
[0026]
Examples of the humectant include hyaluronic acid, dermatan sulfate, chondroitin sulfate, heparan sulfate, keratan sulfate, heparin, chitin and the like, or salts thereof, pyrrolidone carboxylic acid or salt thereof, trehalose and the like.
[0027]
Examples of the whitening agent include ascorbic acid (ascorbic acid, sodium ascorbate, potassium ascorbate, magnesium ascorbate, calcium ascorbate and the like, ascorbic acid sulfate esters such as ascorbic acid-2-sodium sulfate, and ascorbyl phosphate. Acid, sodium ascorbate phosphate, potassium ascorbate phosphate, magnesium ascorbate phosphate, calcium ascorbate phosphate, ascorbate phosphate, ascorbate monostearate, ascorbate monopalmitate, ascorbate monooleate, ascorbate distearate , Ascorbic acid dipalmitate, ascorbic acid fatty acid ester such as ascorbic acid dioleate, ascorbic acid-2-glu Ascorbic acid glucoside, etc.) arbutin such Sid, placenta extract, kojic acid, rice bran extract, rucinol, Kujin'ekisu and the like.
[0028]
Examples of the thickener include carboxymethylcellulose, carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, xanthan gum, carrageenan, alginate, pectin, gum arabic, karaya gum, tragacanth gum, tamarind gum, agate powder, polyethylene glycol Etc.
[0029]
Examples of the preservative include parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, phenoxyethanol, and the like.
[0030]
Examples of the surfactant include polyoxyethylene [hereinafter abbreviated as POE-] alkyl ether (POE-oleyl ether, POE-cetyl ether, etc.), POE-branched alkyl ether (POE-octyldodecyl alcohol, POE-2-). Decyltetradecyl alcohol), sorbitan esters (sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, etc.), POE-sorbitan esters (POE-sorbitan monooleate, POE-sorbitan monoisostearate, POE- Sorbitan monolaurate, etc.), glycerin fatty acid esters (glyceryl monooleate, glyceryl monostearate, glyceryl monomyristate, etc.), POE-glycerin fatty acid esters (POE-glyceryl monooleate, POE-glyceryl monostearate, POE- Glyceryl monomi Restate, etc.), POE-dihydrocholesterol ether, POE-hardened castor oil fatty acid ester (POE-hardened castor oil, POE-hardened castor oil isostearate, etc.), POE-alkyl aryl ether (POE-octylphenol ether, etc.), glycerol ether (Glycerol monoisostearate, glycerol monomyristate, etc.), POE-glycerol ether (POE-glycerol monoisostearate, POE-glycerol monomyristate, etc.), polyglycerol fatty acid ester (diglyceryl monostearate, decaglyceryl iso) Stearates, decaglyceryl decaisostearate distearyl diisostearate, etc., salts of higher fatty acids (myristic acid, stearic acid, palmitic acid, behenic acid, isostearic acid, oleic acid, etc.) (potassium, sodium Arm, diethanolamine, triethanolamine, etc.), phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidyl inositol, phosphatidyl serine and their lyso-form) and the like.
[0031]
【Example】
Next, the present invention will be described in more detail based on examples and test examples. The present invention is not limited to these.
[0032]
[Example 1] and [Comparative Examples 1 to 4]
In the blending ratio shown in Table 1, the raw materials of the oil phase and the water phase are uniformly mixed at 70 ° C., and the water phase is gradually added and emulsified while stirring the oil phase, and then continuously stirred at a low speed. A cream was prepared by cooling to about 30 ° C.
[0033]
Incidentally, MCPC in the tables are phosphatidylcholines for use in the present invention, their preparation, egg yolk lysophosphatidylcholine containing a linear fatty acid residue of R 1 is C 14 -C 22 (QP Corp. "yolk lysolecithin LPC -1 (trade name) ") and n-octanoic acid having 8 carbon atoms were used in accordance with the above-described production methods (1) to (3). The amount of each raw material is as follows.
(A) Egg yolk lysophosphatidylcholine 20 g
The other ingredients are 1 mol of egg yolk lysophosphatidylcholine,
(B) n-octanoic acid 1.8 moles (c) 4-dimethylaminopyridine 2.4 moles (d) N, N′-dicyclohexylcarbodiimide 2.8 moles in an amount of (b), (c ) And (d) were used.
[0034]
In addition, lysophosphatidylcholine and hydrogenated phospholipid in the table are “yolk yolk lysolecithin LPC-1 (trade name)” and “yolk lecithin PL-100P” manufactured by QP Corporation, which are used as raw materials for MCPC, respectively. (Product name) "was used.
[0035]
[Table 1]
[0036]
[Test example]
[Test Example 1]
Each cream obtained in Example 1 and Comparative Examples 1 to 4 was subjected to a panel test using 75 women (average age of 30 years) who were chronically dry and suffering from rough skin as subjects.
[0037]
First, in order to confirm the skin condition, a preliminary questionnaire was conducted in advance, and based on the result of this preliminary questionnaire, the skin condition was divided into five groups of 15 people per group. For one group, any one of the above creams was used for 6 weeks before morning and before going to bed, and a questionnaire survey was conducted on the skin condition before and after use. The contents of the questionnaire survey are the answers to the skin condition based on the following evaluation criteria. The obtained results are shown in Table 2.
It was not clear which cream was used by the subjects.
[0038]
<Rank>
A: It was greatly improved.
B: Improved.
C: Slightly improved.
D: No change is observed.
<Comprehensive evaluation>
A: 8 or more subjects who answered “A: greatly improved” ○: Less than 8 subjects who answered “A: greatly improved” and “A: greatly improved” Or 8 or more subjects who answered “B: improved” Δ: 3 or more subjects who answered “A: greatly improved” or “B: improved” Less than x: Less than three panelists responded that “A: very improved” or “B: improved” [0039]
[Table 2]
[0040]
From Table 2, it is understood that the cosmetic (Example 1) containing MCPC of the present invention and a hard protein hydrolyzate (hydrolyzed collagen) has an excellent skin improvement effect. In other words, the cosmetics containing only the hard protein hydrolyzate (Comparative Example 1) and the cosmetics containing only MCPC (Comparative Example 4) responded that most subjects “slightly improved” The improvement effect could not be expected. In addition, the cosmetic containing the hard protein hydrolyzate and lysophosphatidylcholine or hydrogenated phospholipid (Comparative Example 2 or 3) is slightly more than the cosmetic containing only the hard protein hydrolyzate or only MCPC, Although it was improved, the majority of the subjects replied “Slightly improved” and it was difficult to say that they had a sufficient skin improvement effect.
On the other hand, the cosmetics containing MCPC and the hard protein hydrolyzate (Example 1), most subjects answered “very improved” or “improved”, and other cosmetics. It had an excellent skin improvement effect.
[0041]
[Example 2]
After mixing the raw materials of the oil phase and water phase at room temperature or evenly by temporarily warming them as necessary at the blending ratio shown below, the water phase is gradually added and mixed while stirring the oil phase. Water was prepared.
The obtained lotion was excellent in skin improvement effect.
MCPC was produced according to Example 1 except that n-octanoic acid used as a raw material when producing MCPC in Example 1 was replaced with n-decanoic acid.
[0042]
[0043]
【The invention's effect】
As described above, the cosmetic composition of the present invention is composed of a phosphatidylcholine, a hard protein and a hydrated protein thereof, in which the fatty acid residue at the 1st position of the glycero skeleton is a linear long-chain fatty acid and the 2nd position is a linear saturated medium-chain fatty acid Combined with at least one selected from degradation products or derivatives thereof, soy lecithin, egg yolk lecithin or their hydrogenated products, monoacyl lysolecithin, hard protein and hydrolyzate thereof, which have been conventionally used Or the cosmetics which have the outstanding skin improvement effect compared with the cosmetics combined with at least 1 or more types chosen from the derivative (s) are obtained.
Claims (2)
で表されるホスファチジルコリンと、硬タンパク質及びその加水分解物あるいはその誘導体から選ばれる少なくとも1種以上とを含有することを特徴とする化粧料。General formula
A cosmetic comprising the phosphatidylcholine represented by the formula: and at least one selected from hard proteins and hydrolysates or derivatives thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002304097A JP3836066B2 (en) | 2002-10-18 | 2002-10-18 | Cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002304097A JP3836066B2 (en) | 2002-10-18 | 2002-10-18 | Cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004137206A JP2004137206A (en) | 2004-05-13 |
JP3836066B2 true JP3836066B2 (en) | 2006-10-18 |
Family
ID=32451627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002304097A Expired - Fee Related JP3836066B2 (en) | 2002-10-18 | 2002-10-18 | Cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3836066B2 (en) |
-
2002
- 2002-10-18 JP JP2002304097A patent/JP3836066B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004137206A (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5443840A (en) | Cosmetic and/or pharmaceutical composition containing a dispersion of lipid vesicles, process for the preparation of the said dispersion and dispersion of lipid vesicles | |
US5614215A (en) | Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use | |
DE69811263T2 (en) | CONJUGATED LINOLIC ACID CONTAINING DISTRIBUTION SYSTEM IN COSMETICS | |
Acid | Final report on the safety assessment of oleic acid, laurie acid, palmitic acid, myristic acid, and stearic acid | |
AU687931B2 (en) | Phospholipids as a vector for an active molecule, their preparation and their use in cosmetic or dermatological compositions | |
CN1143668C (en) | Ascorbyl-phosphoryl-cholesterol | |
JP4387464B2 (en) | Tocopherol esters and their use in cosmetics and pharmaceuticals | |
US6369042B1 (en) | Antioxidative vitamin B6 analogs | |
DE69002539T2 (en) | Cosmetic preparation against aging of the skin. | |
JP2000327558A (en) | Method for increasing cell rejuvenscence speed | |
JP2006070048A (en) | Application of ascorbic acid derivatives for augmenting the synthesis of epidermal ceramides | |
JP2005179313A (en) | Method for producing base agent for skin cosmetic, and skin cosmetic | |
KR100556682B1 (en) | Retinoylamide based derivatives of sphingoid bases | |
JP4589865B2 (en) | N-acetylglucosamine derivatives and uses thereof | |
JP3836066B2 (en) | Cosmetics | |
KR101461625B1 (en) | Composition for ameliorating or treating skin barrier damage, or for improving or reinforcing skin barrier function comprising 16-hydroxyhexadecanoic phytosphingosine | |
JP3728269B2 (en) | Cosmetics | |
JP3836065B2 (en) | Cosmetics | |
JP3728270B2 (en) | Cosmetics | |
JP3751261B2 (en) | Cosmetics | |
JP2004059496A (en) | Cosmetic | |
JP4101558B2 (en) | Transparent cosmetics | |
JP2003146872A (en) | Lipid dispersion composition and external preparation for skin | |
JP4067211B2 (en) | Skin preparation | |
JP2005089390A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050322 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060725 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090804 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120804 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150804 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |